Membranous glomerulonephropathy associated with psoriasis vulgaris.
Sakemi
T
T
Hayashida
R
R
Ikeda
Y
Y
Baba
N
N
Nishihara
G
G
Kohda
H
H
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D003176:Complement C3 / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D015433:Glomerulonephritis, Membranous / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007678:Kidney Glomerulus / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
D000893:Anti-Inflammatory Agents; D003176:Complement C3; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone